Amphotericin B (AmB) is widely used for treating severe systemic fungal infections. However, long-term AmB treatment is invariably associated with adverse effects like anemia. The erythropoietin (EPO) suppression by AmB has been proposed to contribute to the development of anemia. However, the mechanism whereby EPO is suppressed remains obscure. In this study we investigated the possibility that AmB inhibits the transcription of the EPO gene by inactivating HIF-1, which is a known key transcription factor and regulator of EPO expression. EPO mRNA levels were markedly attenuated by AmB treatment both in rat kidneys and in Hep3B cells. AmB inactivated the transcriptional activity of HIF-1α, but did not affect the expression or localization of HIF-1 subunits. Moreover, AmB was found to specifically repress the C-terminal transactivation domain (CAD) of HIF-1α, and this repression by AmB required Asn803, a target site of the factor inhibiting HIF-1 (FIH); moreover, this repressive effect was reversed by FIH inhibitors. Furthermore, AmB stimulated CAD-FIH interaction and inhibited the p300 recruitment by CAD. We propose that this mechanism underlies the unexplained anemia associated with AmB therapy.
INTRODUCTION
Amphotericin B (AmB) is a polyene macrolide antifungal agent with broad-spectrum activity, and has been popularly used as a therapeutic agent for treating systemic mycoses for more than 40 years. 1 Currently, an increasing number of patients are being treated with this agent in immune deficient conditions, such as AIDS, malignancy, anticancer treatment, or organ transplantation. 2 The antifungal activity of AmB is due to its binding ergosterol, a sterol present in the fungal cell wall, which results in membrane disruption and cytoplasmic component leakage. At higher concentrations, AmB also binds to cholesterol in the plasma membrane of mammalian cells, which may be associated with its frequently encountered toxic effects. 3 Despite these adverse effects and the recent development of new antifungal agents, AmB remains the drug of choice for treating severe systemic fungal infections. 3 Since prolonged therapy is required to cure systemic mycoses, most patients experience the adverse effects of AmB. Nephrotoxicity is the most serious problem because it occurs in up to 80% of patients. 4 Another serious problem is anemia, which occurs in 24% of total patients treated with AmB. In cases of prolonged therapy, i.e., > 1 month, anemia occurs in more than 90% of patients 3, 5 . The anemia produced is normocytic and normochromic, and reticulocyte numbers in anemic patients are below the normal range. 5, 6 It was concluded that this anemia is caused by a drug-induced suppression of erythrocyte production rather than by an increased rate of erythrocyte destruction. In spite of anemia, AmB-treated patients show low plasma levels of erythropoietin (EPO), which is markedly induced in case of anemia with other etiologies. Therefore, the reduced production of EPO is considered to be either a causative or an aggravating factor in AmB-induced anemia. 6, 7 In fact, supplementation with recombinant EPO protein has been attempted to correct this anemia 3 . However, the mechanism underlying EPO suppression by AmB was unknown.
EPO is a glycoprotein hormone and a primary regulator of the red blood cell production, and Epo
For personal use only. on . by guest www.bloodjournal.org From 4 production by the kidneys increases in response to anemia. 8 This increase occurs primarily at the transcriptional level, and involves transcriptional induction via the binding of a transcription factor, hypoxia-inducible factor-1 (HIF-1), to a conserved sequence, 5'-RCGTG-3', in the hypoxia response element (HRE) located in the 3'-flanking region of the EPO gene. 9 HIF-1 is a heterodimeric transcription factor composed of two basic helix-loop-helix (bHLH) proteins of the PAS family, namely, HIF-1α and HIF-1β, the latter of which is also designated as aryl hydrocarbon nuclear receptor translocator (ARNT).
Of these, HIF-1α is a key protein, as it determines the formation of HIF-1 and transactivates the EPO gene. Moreover, HIF-1 functions as a master regulator of oxygen homeostasis because it directly regulates the transcription of more than 40 kinds of hypoxia-inducible genes. 10 The N-terminal portion of HIF-1α contains bHLH and PAS domains, which are essential for DNA binding and dimerization with ARNT. 11, 12 Its C-terminal portion contains two transactivation domains (TAD), which are localized at amino acids 531-575, N-terminal TAD (NAD), and at 786-826, C-terminal TAD (CAD). 13, 14 Its middle portion contains the Pro-Ser-Thr rich oxygen-dependent degradation domain (ODDD; aa. 401-603), which determines its protein stability. 15 Under normoxic conditions, HIF-1-prolyl hydroxylases (PHD1-3) hydroxylate two proline residues in the LXXLAP motif at the N-terminal end (Pro402) and in the C-terminal end (Pro564) within the ODDD. [16] [17] [18] [19] [20] Von Hippel-Lindau tumor suppressor protein (pVHL) then binds to the modified motifs, which results in the ubiquitination and proteasomal degradation of HIF-1α. 21, 22 Since the enzymatic reaction of PHD requires molecular oxygen as a substrate, hypoxia limits this hydroxylation, thereby stabilizing HIF-1α and precluding its binding of pVHL. It was found recently that ARD1 acetylates Lys532 within the ODDD and that this enhances the interaction between HIF-1α and pVHL. 23 This lysyl acetylation, in addition to prolyl hydroxylation, is also viewed as a regulatory mechanism that underlies the stability of HIF-1α. In addition to its protein stabilization, the modulation of the transcriptional activity of HIF-1α regulates hypoxia-inducible gene expression. In an experiment using a fusion protein containing the Gal4 DNA-binding domain and CAD,
For personal use only. on . by guest www.bloodjournal.org From although the protein stability was unaffected by hypoxia, the transcriptional activity of CAD was found to be enhanced under hypoxic conditions. It was also found that CAD is hydroxylated at an asparagine residue (803) under normoxic conditions, and that this results in a blockade of the recruitment of p300 coactivator. 24 This hydroxylation is promoted by an asparagine hydroxylase, factor-inhibiting HIF1 (FIH). [25] [26] [27] Under hypoxic conditions, asparagine hydroxylation is inhibited due to limited molecular oxygen, and CAD remains unmodified and activated.
To understand the mechanism underlying AmB-induced anemia, we firstly confirmed that AmB suppresses EPO production at the transcriptional level in vivo and in vitro. We also designed experiments to test the possibility that AmB inhibits HIF-1. AmB was found to attenuate the HIF-1-dependent stimulation of the EPO enhancer activity, and to repress the transcriptional activation of HIF-1α, but it did not inhibit the expression or the nuclear translocation of HIF-1 subunits. Moreover, AmB deregulated the oxygen sensing process to determine CAD activity, and this AmB effect was rescued by FIH inhibitors.
Immunoprecipitation and mammalian two-hybrid studies revealed that AmB enhanced FIH binding to CAD and blocked p300 recruitment by CAD. These results suggest that FIH repression of HIF-1 transcriptional activity is responsible for the AmB-induced suppression of EPO transcription.
MATERIALS AND METHODS

Reagents and antibodies.
Amphotericin B (AmB), desferrioxamine (DFO) and other chemicals were purchased from Sigma- HIF-1α antiserum was generated in rabbits against a bacterially expressed fragment encompassing amino acids 418-698 of human HIF-1α, as previously described. 28 Antibodies, goat anti-ARNT, mouse anti-β-actin, rabbit anti-NF-κB P50, rabbit anti-Gal4 were purchased from SantaCruz Biotechnology Inc. (Santa Cruz, CA). Rat anti-HA and mouse anti-EPO monoclonal antibodies were obtained from Roche Ltd.
(Basel, Switzerland) and In2Gen Co. Ltd. (Seoul, Korea).
Procedures for hypoxia and anemia models.
Specific pathogen-free adult male Sprague-Dawley rats were used throughout. For in vivo hypoxia, rats were exposed to 10% O 2 at 1 atmosphere in an air-tight plastic chamber for 16 hours. Humidified gas was supplied continuously to the chamber to minimize pCO 2 changes. After sacrifice, kidneys were excised and quickly frozen in liquid nitrogen. Rats were injected with AmB (4 mg/kg in four divided doses) before hypoxic treatment. To induce anemia, rats were anesthetized with pentobarbital sodium (50 mg/kg), and mechanically ventilated. After incising the abdominal wall, we aspirated blood (20 ml/kg body weight) from the inferior vena cava, and injected Tyrode solution to maintain the systemic circulation. After the abdomen was closed with 4-0 silk sutures, the animal was allowed to recover. Rats were injected with AmB (1 mg/kg, single iv. injection) immediately after the surgery. Sham operations were performed in an identical manner, except for blood aspiration. All animal procedures were performed according to the established procedures described in the Seoul National University Laboratory Animal Maintenance Manual.
Cell culture and treatment.
Hep3B and HEK293 cell-lines were obtained from ATCC, and cultured in α-modified Eagle's medium or Dulbecco's modified Eagle's medium, supplemented with 10% heat-inactivated fetal calf serum, 100 units/ml penicillin, and 100 µg/ml streptomycin, in a humidified atmosphere containing 5% CO 2 at 37°C.
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Preparation of expression plasmids and siRNA, and transfection.
Hemagglutinin (HA)-tagged HIF-1α expression plasmid (pcDNA3) was constructed as described previously. 29 The plasmid used to stably express hypoxia-activated HIF-1α mutant (sh-HIF-1α) was made by deleting three degradation motifs (aa. 397-405, 513-553, and 554-595) using a PCR-based mutagenesis kit (Stratagene, Cedar Creek, TX). 30 The plasmid used to stably express constitutively activated HIF-1α mutant (sc-HIF-1α) was made by substituting Ala803 for Asn803 in sh-HIF-1α using a QuickChange TM site-directed mutagenesis kit (Stratagene). The Gal4-CAD plasmid was constructed by inserting HIF-1α CAD (C-terminal transactivation domain, aa. 776-826) into EcoRI/BamHI-digested pCMX-G4(N), and the Gal4-CAD mutant plasmids were generated by site-directed mutagenesis. 31 The (His)VP16-C/H1 plasmid was constructed by inserting the p300 C/H1 domain into EcoRI/XbaI-digested p(His)VP16 (Clontech, Palo Alto, CA). 31 The HA-FIH plasmid was constructed by inserting full-length For personal use only. on October 23, 2017. by guest www.bloodjournal.org From
Reporter assays.
Luciferase reporter genes, containing the EPO enhancer region, the HRE-mutated EPO enhancer region, or the Gal4-binding motif, were constructed as previously described. 31 Hep3B and HEK293 cells were co-transfected with 0.5 μg each of reporter gene and plasmid cytomegalovirus-β-gal and/or plasmids of HIF-1α or Gal4-CAD, using the calcium phosphate method. pcDNA was added to ensure that the final DNA concentrations in both the control and experimental groups were at similar levels. After being allowed to stabilize for 48 hours, cells were incubated under either normoxic or hypoxic conditions, in the absence or in the presence of AmB for 16 hours, and then lysed to determine luciferase and β-gal activities.
Immunoblotting of HIF-1 subunits and other proteins.
Total cell lysates were separated on 8% or 10% SDS/polyacrylamide gels, and transferred to an Immobilon-P membrane (Millipore, Bedford, MA). Membranes were blocked with 5% nonfat milk in Tris-buffered saline containing 0.1% Tween-20 (TTBS) at room temperature for 1 hour and then incubated overnight at 4 o C with a primary antibody diluted 1:1000 in 5% nonfat milk in TTBS.
Membranes were incubated with a horseradish peroxidase-conjugated secondary antibody (diluted 1:5000 in 5% nonfat milk in TTBS) for 2 hours, and the antigen-antibody complexes were visualized using an Enhanced Chemiluminescence Plus kit (Amersham Biosciences Corp., Piscataway, NJ).
Semiquantitative RT-PCR for EPO mRNA and other HIF-1-induced mRNAs.
To quantify mRNA levels we used a highly sensitive, semi-quantitative RT-PCR, as previously described. 28 Total RNAs were isolated from cultured cells or rat kidney tissues using TRIZOL (GIBCO/BRL). After verifying their qualities on a 1% denaturing agarose gel, one μg of total RNAs were reverse-transcribed at 48 GGCACCACACTTTCTACAAT and TCTCTTGCTCGAAGTCTAGG. Primers for human EPO, VEGF, PGK 1, enolase 1, and β-actin were constructed as previously described.
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TUNEL and MTT assays
To evaluate renal toxicity, the ApopTag in situ apoptosis detection kit (Oncor, Gaithersburg, MD) was used. Rat kidneys were fixed with formalin and embedded in paraffin. Six-micrometer sections were dewaxed and treated with proteinase K, then incubated with equilibration buffer for 10 min, followed by incubation with working-strength TdT enzyme solution at 37°C for 2 h. The reaction was terminated by incubation in stop/wash buffer. Sections were then incubated with antidigoxigenin peroxidase and then incubated with diaminobenzidine and 0.01% H 2 O 2 for 5 min. The sections were counterstained with hematoxylin and examined by microscopy. To evaluate cytotoxicity, the Sigma MTT labeling kit was used. Cells were grown in 12 well plates in 1 ml medium per well. After incubating with AmB for 16 hours, 100 μl of an MTT labeling reagent (5 mg/ml) was added, and incubation was continues in the CO 2 chamber for 3 h. After solubilizing the blue formazan crystal with acidified isopropanol, formazan levels were determined at 570 nm.
Statistical analysis. All data were analyzed using Microsoft Excel 2000 software, and results are expressed as means and standard deviations. We used the unpaired Student's T test (SPSS 10.0 for
Windows software) to compare reporter activities between control and AmB-treated groups. Differences were considered significant when P was <0.05. All statistical tests were two-sided.
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From
RESULTS
AmB blunts EPO response to hypoxia in vivo and in vitro
Although the suppression of EPO production by AmB has been well-defined clinically, it has not been determined whether AmB suppresses EPO production in an experimental situation. When rats had been exposed under 10% O 2 , EPO mRNA and protein levels increased in the kidneys, but this EPO induction was markedly diminished in AmB-treated rats (Fig. 1a) . We also examined the EPO suppression effect of AmB in anemic rats. The EPO mRNA expression was induced after bleeding, and this induction was reduced by AmB (Fig. 1b) . In such conditions, the microscopic structures of the kidneys were not changed (data not shown) and apoptotic death was not observed in AmB-treated kidneys, whereas massive cell death occurred in the renal medulla of rats treated with a renal toxin, KBrO 3 (Fig. 1c) . To examine the effect of AmB on EPO response to hypoxia in vitro, we firstly determined the experimental AmB concentrations. Since 2.5 μg/ml of AmB is recommended for preventing fungal contamination, we reasoned that AmB can be safely used at around this concentration. Moreover, Hep3B and HEK293 cells were not obviously injured by treatment with AmB at up to 10 μg/ml for 16 h (Fig. 1d) . Thus we used AmB at <10 μg/ml throughout the experiments. After exposing EPO-producing Hep3B cells to hypoxia, EPO mRNA was markedly enhanced versus the normoxic control (Fig. 1e) . To examine the effect of AmB on EPO expression, cells were treated with AmB under hypoxic conditions. AmB at 2.5 μg/ml or more significantly reduced EPO mRNA levels in a dose-dependent manner. In addition to EPO, other HIF-1 target gene expression was also dose-dependently reduced by AmB (Fig. 1e) . These results indicate that as occurs in patients, EPO production is suppressed by AmB both in rats and in Hep3B cells, and suggest that HIF-1 inhibition is responsible for the EPO suppression.
AmB attenuates the HIF-1-dependent stimulation of EPO enhancer
Since hypoxia induces EPO gene transcription due to HIF-1 targeting its 3'-enhancer segment, we examined the effect of AmB on the activity of an EPO enhancer reporter. In hypoxic Hep3B and 293 cells, this reporter activity increased 25-and 5.5-fold, respectively, versus that of normoxic cells.
However, AmB reduced this activity in a dose-dependent manner ( Fig. 2a and 2c) . In contrast, in cells transfected with an EPO enhancer reporter plasmid mutated at the HIF-1-binding site, reporter activity was unaffected by either hypoxia or AmB (Fig. 2b and 2d ), suggesting that AmB does not influence the HIF-1-independent transcription of the reporter gene. These results indicate that AmB blocks the interaction between HIF-1 and the EPO enhancer, thus reducing EPO mRNA levels. Basically, HIF-1 activation requires that both HIF-1 subunits, HIF-1α and ARNT, should be present and translocated to the nucleus. Thus, we examined whether AmB reduces the levels of HIF-1 subunits in hypoxic cells. AmB did not reduce the cellular levels of either HIF-1α or ARNT in Hep3B or HEK293 cells (Fig. 2e, left panel). In the nuclear fractions, HIF-1α levels were not affected by AmB in Hep3B cells, but slightly reduced in HEK293 cells (Fig. 2e, right panel) . However, the reduction in nuclear HIF-1α occurred only in HEK293, and the reduction degree was not significant compared to that in HIF-1 activity. Therefore, either HIF-1 expression or nuclear translocation is unlikely to be responsible for the HIF-1 inhibition by AmB.
HIF-1α repression by amphotericin B requires Asn803 and FIH
To test the possibility that AmB inhibits HIF-1 at the transcriptional level, we expressed HIF-1α or its stable mutants, structures of which are illustrated in the upper panel of Fig. 3 . Stable, hypoxia-activated (sh)-HIF-1α is expressed stably under normoxic conditions but its transcriptional activity is O 2 -dependently regulated. In contrast, stable, constitutively activated (sc)
hypoxia-activated transcription and is active, regardless of O 2 tension. As expected, the EPO reporter activity was enhanced by wild-type HIF-1α and sensitively repressed by AmB (Fig. 3a) . sh-HIF-1α transcriptional activity was also inhibited by AmB (Fig. 3b) . However, sc-HIF-1α showed no significant change in transcriptional activity due to AmB (Fig. 3c) . The slight increase of reporter activity by hypoxia (the 2 nd bar in Fig. 3c ) may be due to the reporter activation by endogenous HIF-1α. These results suggest that AmB inhibits the hypoxic activation of CAD by targeting Asn803. To confirm that AmB specifically blocks the hypoxic activation of CAD, we co-expressed a Gal4-CAD fusion protein (illustrated in Fig. 4 , upper panel) with a Gal4-Luc reporter plasmid in HEK293 cells. This fusion protein was activated under hypoxic conditions and this activation was significantly diminished by AmB (Fig.   4a ). However, when Asn803 in CAD had been replaced with alanine or aspartate, AmB showed no effect on the Gal4-CAD mutants ( Fig. 4b and 4c) . When Cys800, which is responsible for the redox-dependent regulation of CAD, was mutated, the induction fold of CAD activity under hypoxic conditions reduced slightly, but was significantly reduced by AmB treatment (Fig. 4d) . These results suggest that AmB represses CAD activity by targeting Asn803 and that this AmB action is possible when O 2 , even at low levels, is available for an O 2 -sensing system to regulate CAD activity.
Since Asn803 hydroxylation by FIH is a key step in the inactivation of CAD, we hypothesized that AmB stimulates this inhibitory process, and therefore we examined the inhibitory effect of AmB in cells that FIH was overexpressed or knocked down. The HIF-1α repression by AmB was significantly augmented in FIH-overexpressing cells (Fig. 5b) and inversely diminished in FIH-silenced cells (Fig. 5d ).
In cells co-transfected with control DNA (Fig. 5a ) or siRNA (Fig. 5c ), the AmB effect was not different from that in untransfected cells (Fig. 4a) . These results suggest that AmB augments the CAD inhibition by FIH under hypoxic conditions. However, it is uncertain that FIH can be activated under hypoxic conditions because oxygen is essentially required for the enzymatic action of FIH. 27 To examine whether
FIH is functional under hypoxic (1% O 2 ) conditions, we expressed or knocked-down FIH. The hypoxic
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CAD activity was significantly enhanced by FIH siRNA and suppressed by FIH expression (Fig. 5e, right panel). This result suggests that endogenous FIH is not completely inactivated and expressed FIH has activity under hypoxic conditions. FIH activity is limited in such O 2 tension, but remains in part. Thus, it is possible that AmB stimulates the FIH activity remaining under hypoxic conditions. On the other hand, FIH expression showed no further inhibition of CAD activity under normoxic conditions (Fig. 5e left   panel) , which suggests that FIH activity is already saturated. Therefore, CAD activity could not be inhibited by AmB, as shown in Fig. 4a .
The inhibition of FIH recovers HIF-1α activity and EPO expression in vitro and in vivo.
To confirm that FIH is involved in the AmB-induced repression of CAD, we treated cells with FIH inhibitors. The iron chelator, desferrioxamine and the 2-oxoglutarate analogue, DMOG, inhibit FIH because iron and 2-oxoglutarate are co-factors essential for the enzymatic reaction. 27, 33 Both FIH inhibitors at low concentrations effectively reversed CAD inhibition by AmB (Fig. 6a) . Moreover, DMOG at these low concentrations recovered the hypoxic expression of the EPO and other HIF-1 target genes in the presence of AmB (Fig. 6b) . In general, 100 μM desferrioxamine and 1 mM DMOG are required to block the oxygen sensing process. However, AmB action was sensitively inhibited by 10 μM desferrioxamine and 1 μM DMOG. Considering that Gal4-CAD protein is not regulated by PHDs, which can be also inhibited by these molecules, the recovery of CAD activity is likely to be a consequence of FIH inhibition.
AmB enhances HIF-1α-FIH binding and inhibits the recruitment of p300
To determine whether AmB stimulates binding between FIH and CAD, we co-expressed Gal4-CAD and HA-tagged FIH and performed a co-immunoprecipitation experiment using anti-Gal4 and anti-HA antibodies. The input data revealed that the amounts of FIH protein were not changed by AmB, and nor
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From was the Gal4 fusion (Fig. 7a, upper and middle panels) . However, FIH binding to CAD was significantly increased in AmB-treated cells, but FIH binding to Gal4 was not (Fig. 7a, lower panel) . FIH is known to inactivate CAD by preventing the interaction between CAD and the C/H1 domain of p300 co-activator.
Thus we examined the CAD-p300 interaction by using a mammalian two-hybrid assay, in which reporter activity was determined by the interaction between Gal4-CAD and C/H1-VP16. Fig. 7b showed that the CAD-p300 interaction was enhanced by hypoxia and that this interaction was significantly inhibited by AmB. These results suggest that AmB enhances the binding activity of FIH to CAD and inhibits the recruitment of p300, thus resulting in a repression of CAD activity under hypoxic conditions.
DISCUSSION
Hypoproliferative anemia, which is due to impairment of erythropoiesis, is secondarily developed in patients who have chronic inflammatory disorders persisting more than a month. These disorders include bacterial or fungal infections, autoimmune diseases, and tumors. In most cases of secondary anemia, correction of the underlying disorder suffices to alleviate the blood abnormality. In this respect, patients infected by fungi could undergo anemic process already before AmB therapy. However, the important thing is the fact that the anemia is aggravated after AmB therapy even though infection is improved. In a clinical study, mean hematocrit fell from 41% before AmB therapy to 27% at therapy completion. 5 This
AmB-induced anemia has also been clinically demonstrated by other research groups. 6, 7 Furthermore, serum EPO levels fall significantly in parallel with hematocrit and hemoglobin reduction during therapy.
Therefore, AmB-induced EPO suppression is considered to aggravate the hypoproliferative anemia.
To date, the mechanism underlying EPO suppression is not understood. It is possible that EPO suppression occurs secondary to the nephrotoxicity induced by AmB, as occurs in chronic renal failure. If so, degrees of anemia and EPO level reduction should be correlated with increased levels of blood urea
For personal use only. on . by guest www.bloodjournal.org From nitrogen (BUN), which is a marker for nephrotoxicity. However, Brandriss et al. 5 and MacGregor et al. 6 reported no such correlation between BUN levels and anemia degree or EPO levels. We also demonstrated that EPO production was suppressed by AmB without microscopic changes and apoptotic cell death in rat kidneys. Therefore, it is believed that EPO suppression can not be explained as being secondary to nephrotoxicity, rather it may be mediated by AmB's specific action on kidney cells. In the present study, we provide an answer to this mystery, namely, that AmB enhances the interaction between FIH and the CAD of HIF-1α, and thus represses CAD activity, which results in an inhibition of EPO gene transcription. Although we can not fully understand the complicated anemia occurring in patients, HIF-1α
repression by FIH is likely to contribute to anemia aggravated after AmB therapy.
Circulating EPO in the adult is mainly produced from cells in and around the proximal tubules of the kidney. Hybridization experiments have demonstrated that EPO mRNA is present in fibroblast-like interstitial cells in the vicinity of the proximal tubules in humans, monkeys, mice, and sheep. 34 EPO mRNA was also found in epithelial cells of the proximal renal tubules. 35 Therefore, toxic drugs that are accumulated around the proximal tubules may perturb these EPO-producing cells, causing impairment of EPO induction in response to hypoxia. AmB could be one of such drugs. Because of its high hydrophobicity, AmB is reabsorbed through the proximal tubule and is accumulated in the kidney. 36 A pharmacokinetic study revealed that the average AmB level was 12.7 μg/ml in the kidneys of rabbits treated with AmB (1 mg/kg/day) for 28 days. 37 It is noteworthy that this renal concentration is higher than the effective concentrations (2.5-10 μg/ml) of AmB in the present study. Therefore, the AmB inhibition of HIF-1α activity or EPO expression might occur in the kidney where AmB is present at > 2.5 μg/ml.
To examine the effect of AmB on EPO expression in the kidney, rats were incubated in the chamber containing 10% oxygen, which is a commonly used condition for whole body hypoxia. On the other hand, the mechanism of AmB-induced HIF-1α repression was studied in cultured cells under 1% oxygen conditions, which is also well established to activate HIF-1α. To assume that the in vitro effect of AmB
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From occurs in rat kidneys, it is necessary to consider what the renal oxygen tension is in rats subjected to 10% oxygen. Recently, Mik et al. 38 measured the renal oxygen tension in anesthetized rats by detecting light emitted from Pd-porphyrin. In rats breathing 37% oxygen, the renal oxygen tension was 43 Torr (5.66%).
Surprisingly, it was found that the oxygen tension dropped extremely to 3.6 Torr (0.47%) in rats breathing 10% oxygen. However, because rats hyperventilated in our experimental settings, the renal oxygen tension may be somehow higher than 0.47%, but not be out of the oxygen range to activate HIF-1α.
Therefore, it is expected that the AmB-induced HIF-1 repression in cultured cells could also occur in the hypoxic kidney.
FIH was first identified in the yeast two-hybrid assay by screening for proteins that interact with CAD, and was characterized as a negative regulator of CAD function. 25 Like PHD enzymes, FIH-1 also belongs to the 2-oxoglutarate (2OG)-dependent dioxygenase superfamily. 39 Moreover, hydroxylation catalyzed by FIH requires ferrous iron and consumes molecular oxygen and 2-oxoglutarate (2-OG). Here iron functions a reaction center whereas molecular oxygen facilitates the hydroxylation of the β-carbon on Asn-803, and 2-OG functions a substrate that accepts the remaining oxygen atom from molecular oxygen, and subsequently undergoes decarboxylation to produce succinate. 39 Thus DFO (iron chelator) and DMOG (2-OG analogue) are used to inhibit the enzymatic reaction of FIH. However, although the enzymatic reaction and the X-ray crystal structure of FIH have been extensively examined, the FIH regulatory mechanism has not been elucidated. Here, we demonstrated that AmB stimulated the inactivation of CAD by FIH without altering FIH expression in the 1% O 2 tension. However, we did not determine how AmB stimulates the action of FIH. To understand this mechanism, we first need to ask: Does AmB regulate FIH activity, or does it modify the CAD of HIF-1α such that it is more accessible to FIH? These questions remain to be addressed by future studies.
The present study demonstrates that two FIH inhibitors effectively recovered CAD repression by AmB. Interestingly, FIH was inhibited by DFO and DMOG at concentrations as low as 10-50 μM and 
